Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

被引：1
|
作者：
Miyauchi, Eisaku
Morita, Satoshi
Nakamura, Atsushi
Hosomi, Yukio
Watanabe, Kana
Ikeda, Satoshi
Seike, Masahiro
Fujita, Yuka
Minato, Koichi
Ko, Ryo
Harada, Toshiyuki
Hagiwara, Koichi
Kobayashi, Kunihiko
Nukiwa, Toshihiro
Inoue, Akira
机构：
[1] Tohoku Univ Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[3] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[5] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[6] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[7] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan
[8] Natl Hosp Org, Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan
[9] Gunma Prefectural Canc Ctr, Dept Resp Med, Ota, Japan
[10] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[11] JCHO Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[12] Jichi Med Univ, Div Pulm Med, Dept Internal Med, Shimotsuke, Tochigi, Japan
[13] Saitama Med Univ, Int Med Ctr, Dept Pulm Med, Hidaka, Japan
[14] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan
[15] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9081
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
    Tomizawa, Yoshio
    Fujita, Yuka
    Tamura, Atsuhisa
    Shirai, Masahiro
    Shibata, Satoshi
    Kawabata, Tsutomu
    Shibayama, Takuo
    Fukai, Shimao
    Kawahra, Masaaki
    Saito, Ryusei
    [J]. LUNG CANCER, 2010, 68 (02) : 269 - 272
  • [42] Quantitative analysis of mutated EGFR transcripts for assessment of gefitinib sensitivity of non-small-cell lung cancer.
    Taniguchi, K
    Koizumi, K
    Orita, N
    Sugimoto, Y
    Okami, J
    Higashiyama, M
    Kodama, K
    Kato, K
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9049S - 9049S
  • [43] A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
    Kim, Hye Ryun
    Jang, Joung Soon
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Jung, Inkyung
    Lee, Ki Hyeong
    Kim, Joo-Hang
    Lee, Dae Ho
    Kim, Sang-We
    Cho, Byoung Chul
    [J]. ONCOTARGET, 2017, 8 (09) : 15943 - 15951
  • [44] Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report
    Watanabe, Hiroko
    Tamura, Tomohiro
    Kagohashi, Katsunori
    Takayashiki, Norio
    Kurishima, Koichi
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (01) : 386 - 388
  • [45] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [46] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    [J]. LUNG CANCER, 2003, 41 : S23 - S28
  • [47] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [48] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [49] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [50] Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
    Genova, C.
    Rossi, G.
    Pezzuto, A.
    Valmadre, G.
    Rijavec, E.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Dal Bello, M. G.
    Boccardo, S.
    Coco, S.
    Alama, A.
    Sini, C.
    Burrafato, G.
    Maggioni, C.
    Bennicelli, E.
    Cerbone, L.
    Zullo, L.
    Ricci, A.
    Grossi, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S829 - S830
12345